The majority of the Phase 3 trials on the cardiovascular outcomes of GLP‐1 RAs recruited participants with either established CVD (usually defined as a previous episode of MI, stroke, revascularization, or coexisting peripheral vascular disease) or those with a high cardiovascular risk. This evidence concerns the gene GLP1R and Stroke.